Classical: acitretin, MTX, CsA, PUVA, NUVB, REPUVA, RENUVB Biological: infliximab, efalizumab, etanercept, adalimumab, for up to 8 mos
Significant reductions in NAPSI scores with all antipsoriatics, except for NUVB; significantly greater with CsA and biological as infliximab and adalimumab at 3 and 6 mos
Phase 1: randomly assigned for CsA (2.5–5 mg/kg/day) or etretinate (0.5–0.75 mg/kg/day) for 10 weeks Phase 2: etretinate group discontinued treatment and continued with topical dithranol; CsA group either tapered or discontinued and replaced with topical dithranol for 12 weeks
After phase 1: significant alleviation of nail involvement in both groups and after phase 2: statistically significant decrease in nail involvement for tapered cyclosporine group
B
: number of patients. NAPSI: nail psoriasis severity index. N/A: not applicable. sc: subcutaneous. po: peroral. MTX: methotrexate. CsA: cyclosporine. MEPC: microemulsion preconcentrate. LoE: level of evidence (A2: randomized, double-blind, controlled trial of good quality, B: randomized controlled trial of poor quality).